NASDAQ:CRNXCrinetics Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.94 -0.72 (-4.08 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$16.57Now: $16.94▼$17.9150-Day Range$15.79MA: $17.85▼$23.2352-Week Range$10.63Now: $16.94▼$26.67Volume94,738 shsAverage Volume370,470 shsMarket Capitalization$556.48 millionP/E RatioN/ADividend YieldN/ABeta1.28 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.00, Crinetics Pharmaceuticals has a potential upside of 106.6% from its current price of $16.94.Amount of Analyst CoverageCrinetics Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesCrinetics Pharmaceuticals has received 84 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCrinetics Pharmaceuticals has received 98 “underperform” votes. (Add your “underperform” vote.)Community SentimentCrinetics Pharmaceuticals has received 53.85% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote “Outperform” if you believe CRNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,734,697.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions62.97% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($2.47) to ($2.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRNX Previous Symbol CUSIPN/A CIKN/A Webwww.crinetics.com Phone858-450-6464Debt Debt-to-Equity Ratio0.04 Current Ratio10.89 Quick Ratio10.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.19 million Price / Sales467.63 Cash FlowN/A Price / Cash FlowN/A Book Value$4.84 per share Price / Book3.50Profitability EPS (Most Recent Fiscal Year)($2.09) Net Income$-50,420,000.00 Net MarginsN/A Return on Equity-47.28% Return on Assets-42.59%Miscellaneous Employees47 Outstanding Shares32,850,000Market Cap$556.48 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:CRNX Rates by TradingView Receive CRNX News and Ratings via Email Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions How has Crinetics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRNX stock has increased by 9.3% and is now trading at $16.94. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Crinetics Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crinetics Pharmaceuticals. When is Crinetics Pharmaceuticals' next earnings date? Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Crinetics Pharmaceuticals. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) posted its quarterly earnings data on Friday, May, 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.08. The company earned $0.07 million during the quarter. View Crinetics Pharmaceuticals' earnings history. What price target have analysts set for CRNX? 3 analysts have issued 1-year target prices for Crinetics Pharmaceuticals' shares. Their forecasts range from $30.00 to $38.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 106.6% from the stock's current price. View analysts' price targets for Crinetics Pharmaceuticals. Has Crinetics Pharmaceuticals been receiving favorable news coverage? Media headlines about CRNX stock have trended negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future. View the latest news about Crinetics Pharmaceuticals. Who are some of Crinetics Pharmaceuticals' key competitors? Some companies that are related to Crinetics Pharmaceuticals include IGM Biosciences (IGMS), TG Therapeutics (TGTX), Pacira Biosciences (PCRX), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Xencor (XNCR), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), Myovant Sciences (MYOV), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Madrigal Pharmaceuticals (MDGL) and Passage Bio (ZNTL). View all competitors. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include Arbutus Biopharma (ABUS), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Immunomedics (IMMU), SCYNEXIS (SCYX), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD) and Apellis Pharmaceuticals (APLS). Who are Crinetics Pharmaceuticals' key executives? Crinetics Pharmaceuticals' management team includes the following people: Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)Dr. Alan S. Krasner, Chief Medical Officer (Age 56)Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53) When did Crinetics Pharmaceuticals IPO? (CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO. What is Crinetics Pharmaceuticals' stock symbol? Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX." How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Crinetics Pharmaceuticals' stock price today? One share of CRNX stock can currently be purchased for approximately $16.94. How big of a company is Crinetics Pharmaceuticals? Crinetics Pharmaceuticals has a market capitalization of $556.48 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe. What is Crinetics Pharmaceuticals' official website? The official website for Crinetics Pharmaceuticals is www.crinetics.com. How can I contact Crinetics Pharmaceuticals? Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected] This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
